RxDoctor Payments DataLook up a doctor →

George Kichura, MD

Interventional Cardiology · Saint Louis, MONPI 1114903507

Payments from drug & device makers

$811,110in general payments, 2019–2025

Across 880 payments — averaging $921.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$466K
  • Novartis$203K
  • AstraZeneca$66K
  • Angiodynamics, Inc.$37K
  • E.r. Squibb & Sons, L.L.C.$14K
  • Regeneron Healthcare Solutions, Inc.$5K
  • plus $20K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen81$466,480
Novartis229$202,947
AstraZeneca52$65,553
Angiodynamics, Inc.8$37,210
E.r. Squibb & Sons, L.L.C.26$14,139
Regeneron Healthcare Solutions, Inc.19$4,849
Sanofi-aventis U.S. LLC31$3,836
Abbott31$2,536
Penumbra, Inc.12$2,499
Medtronic16$1,944
Abiomed6$1,204
Pfizer56$844
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)58$775
Merck32$651
Boehringer Ingelheim33$634
Medicure Pharma Inc.2$600
Johnson & Johnson22$449
Vifor Pharma, Inc.22$307
Amarin Pharma, Inc.10$251
Impulse Dynamics (USA) Inc.3$231
Esperion Therapeutics, Inc.10$225
Alnylam Pharmaceuticals Inc.11$220
Corcept Therapeutics9$219
Shockwave Medical, Inc4$206
Boston Scientific4$202
Lundbeck LLC6$202
Gilead11$187
Novo Nordisk9$165
Actelion Pharmaceuticals US, Inc.7$156
Daiichi Sankyo Inc.3$151
Bayer8$131
Kiniksa Pharmaceuticals, Ltd.5$124
Biotronik Inc.1$121
Kestra Medical Technology Services, Inc.6$108
Lexicon Pharmaceuticals, Inc.4$67
Lilly USA, LLC4$64
Kiniksa Pharmaceuticals International, PLC3$62
Merz North America, Inc.1$57
Otsuka America Pharmaceutical, Inc.3$53
Arbor Pharmaceuticals, Inc.3$38
Pharmacosmos Therapeutics Inc.2$37
Koya Medical, Inc.1$37
Livanova USA, Inc.1$35
Resmed Corp1$34
Biobeat USA Inc.1$32
Amryt Pharma Holdings Ltd2$30
Itamar Medical Inc1$29
Janssen Scientific Affairs, LLC1$27
United Imaging Healthcare North America LLC1$23
United Therapeutics Corporation1$23
Cook Medical LLC1$19
Scpharmaceuticals Inc.1$19
Edwards Lifesciences1$16
Veryan Medical Incorporated1$15
Cardiovascular Systems Inc.1$13
Coala Life Inc1$13
Aegerion Pharmaceuticals, Inc.1$12

How this compares

$811,110 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$127,929
Medicare patients
388
Services billed
1,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →